Koureta Evgenia, Cholongitas Evangelos
First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ann Gastroenterol. 2023 Jul-Aug;36(4):378-391. doi: 10.20524/aog.2023.0806. Epub 2023 May 29.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the world, affecting approximately one fourth of the worldwide population. Glucose metabolism dysregulation and type 2 diabetes mellitus (T2DM), as part of the metabolic syndrome, are important factors implicated in the pathogenesis and progression of NAFLD to nonalcoholic steatohepatitis (NASH) and cirrhosis. Although a great deal of research has already been conducted regarding possible therapeutic medications for NAFLD/NASH, no drugs have been approved until now. Combination therapies in NAFLD seem to represent an attractive approach concerning treatment of the disease, as multiple pathophysiologic pathways contribute to the development and advance of NAFLD. In this review we discuss the impact of combining antidiabetic drugs, focusing on pioglitazone, sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. We also include data from the literature concerning combinations of newer "NAFLD-specific" drugs.
非酒精性脂肪性肝病（NAFLD）是世界上最常见的疾病之一，影响着全球约四分之一的人口。作为代谢综合征的一部分，糖代谢失调和2型糖尿病（T2DM）是NAFLD发病机制以及其进展为非酒精性脂肪性肝炎（NASH）和肝硬化的重要因素。尽管已经针对NAFLD/NASH的可能治疗药物进行了大量研究，但迄今为止尚无药物获批。NAFLD的联合治疗似乎是治疗该疾病的一种有吸引力的方法，因为多种病理生理途径促成了NAFLD的发生和进展。在本综述中，我们讨论联合使用抗糖尿病药物的影响，重点关注吡格列酮、钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂。我们还纳入了文献中有关新型“NAFLD特异性”药物联合使用的数据。
